Previous 10 | Next 10 |
SOUTH SAN FRANCISCO, Calif. , July 7, 2020 /PRNewswire/ -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic non-alcoholic steatohepatitis (NASH) company developing pioneering medicines designed to restore metabolic balance and improve the overall health of NASH patients,...
Akero Therapeutics (NASDAQ: AKRO ) has commenced a public offering of 4.75M common shares. More news on: Akero Therapeutics, Inc., Healthcare stocks news, , Read more ...
SOUTH SAN FRANCISCO, Calif. , July 6, 2020 /PRNewswire/ -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic non-alcoholic steatohepatitis (NASH) company developing pioneering medicines designed to restore metabolic balance and improve the overall health of NASH patients, a...
Corcept Therapeutics Starts Phase 3 Pancreatic Cancer Trial Corcept Therapeutics Inc. ( CORT ) announced enrollment of the first participant in its Phase 3 trial RELIANT. The trial seeks to evaluate relacorilant in conjunction with nab-paclitaxel for treating patients with metastatic pan...
The following slide deck was published by Akero Therapeutics, Inc. in conjunction with this Read more ...
Gainers: MYOS RENS Technology (NASDAQ: MYOS ) +210% . More news on: MYOS RENS Technology Inc., Liminal BioSciences Inc., YRC Worldwide Inc., Stocks on the move, , Read more ...
YRC Worldwide (NASDAQ: YRCW ) +123% on receiving $700M CARES act loan from U.S. Treasury. More news on: YRC Worldwide Inc., T2 Biosystems, Inc., Akero Therapeutics, Inc., Stocks on the move, , Read more ...
Akero Therapeutics (NASDAQ: AKRO ) jumps +43% AH, after the company announce results of a 16-week analysis of secondary and exploratory endpoints from its Phase 2a BALANCED study of its lead candidate efruxifermin (EFX), formerly known as AKR-001, in nonalcoholic steatohepatiti...
Gainers: AKRO +33.8% . ETNB +21.1% . FDX +8.9% . AKCA +5.8% . UPS +5.0% . More news on: Akero Therapeutics, Inc., 89bio, Inc., FedEx Corporation, Stocks on the move, , Read more ...
SOUTH SAN FRANCISCO, Calif. , June 30, 2020 /PRNewswire/ -- Akero Therapeutics, Inc. (Nasdaq: AKRO) today announced results of a 16-week analysis of secondary and exploratory endpoints in its Phase 2a BALANCED study of efruxifermin (EFX), formerly known as AKR-001, in patients with n...
News, Short Squeeze, Breakout and More Instantly...
Akero Therapeutics Inc. Company Name:
AKRO Stock Symbol:
NASDAQ Market:
Akero Therapeutics Inc. Website:
2024-07-09 15:02:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-12 10:00:04 ET Edward Nash from Canaccord Genuity issued a price target of $56.00 for AKRO on 2024-06-12 07:44:00. The adjusted price target was set to $56.00. At the time of the announcement, AKRO was trading at $23.43. The overall price target consensus is at $...
SOUTH SAN FRANCISCO, Calif., June 11, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced initiation of the ...